Are there Cochrane reviews on device-based treatments for dryness?
Yes—Cochrane and other systematic reviews have examined energy-based vaginal devices (laser/radiofrequency) relevant to genitourinary syndrome of menopause (GSM), though the evidence base is still evolving. Reviews often report small, short-term trials with varied methods, making it hard to draw firm conclusions compared with guideline-backed options like moisturisers, lubricants and local vaginal oestrogen. Devices may be considered as adjuncts after foundations are optimised, with expectations set around timelines and uncertainty. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Are there Cochrane reviews on device-based treatments for dryness? Energy-based devices (most commonly fractional CO2 or erbium lasers, and various radiofrequency systems) have been studied for symptoms that overlap with genitourinary syndrome of menopause (GSM)—such as vaginal dryness, soreness and dyspareunia—and for related conditions like stress urinary incontinence. Cochrane and other high-quality reviewers have looked at these technologies, but study numbers are modest, follow-up is often short, and methods vary (different device settings, treatment counts and outcome scales). This means the certainty of evidence is typically low to moderate, and it is difficult to compare device results directly with guideline-backed therapies like scheduled vaginal moisturisers, compatible lubricants and low-dose local vaginal oestrogen.
What the reviews tend to find. Small trials sometimes report improvements in vaginal symptom scores and vaginal health indices after a short series of sessions, but the durability of benefit beyond a few months is uncertain, and sham-controlled data are limited. Where head-to-head comparisons with local oestrogen exist, they are few and underpowered. Safety reports generally describe transient effects (warmth, spotting, discharge, local tenderness), yet registries emphasise the need for appropriate device selection, correct intended use, and post-market vigilance.
How this fits with UK care. In the UK, first-line management of GSM remains non-hormonal foundations—a scheduled vaginal moisturiser plus a generous, compatible lubricant tailored to your needs—and, when symptoms affect quality of life, local vaginal oestrogen (or DHEA) per national guidance. Devices are best considered as adjuncts rather than replacements, reserved for selected people after foundations and local therapy are optimised, and after discussing the strength and limits of evidence, the likelihood of needing maintenance, and costs.
Making a practical plan. If you are curious about devices, start by mapping your main limiter (vestibular “paper-cut” splits, insertional sting, deeper pressure, urinary urgency/frequency). Many women improve substantially by targeting the vestibule/posterior fourchette with correct placement of creams (including local oestrogen) and using a silicone-based lubricant for longer glide if the entrance is especially tender. To see how we stage decisions step by step, review our treatment steps, and for what benefits we monitor over time, see treatment benefits. Devices, if chosen, should be UKCA/CE-marked for intimate use and delivered with clear aftercare and red-flag advice.
Setting expectations. Symptom relief from lubricants is immediate but short-lived; moisturisers improve day-to-day comfort within days; local oestrogen/DHEA typically shows clearer change by 2–6 weeks; device-related changes, where present, are usually gradual across a short series (often 2–3 sessions spaced 4–8 weeks apart). Because long-term data are limited, you should expect a review at 6–12 weeks and again later to decide whether maintenance is sensible or whether foundations alone suffice.
Clinical Context
Who might consider devices? People whose main symptoms persist despite excellent foundations and well-placed local therapy—e.g., ongoing vestibular sting or frequent micro-tears limiting intimacy or movement—and who understand the evidence uncertainties and potential need for maintenance sessions.
Who should defer devices for now? Anyone with red flags (malodorous green/grey discharge, intense itch with thick white discharge, fever, visible blood in urine, or new post-menopausal bleeding), active BV/thrush/UTI, or unclear diagnosis. If deep pelvic pain or psychosexual factors dominate, pelvic health physiotherapy, graded dilators and psychosexual support usually add more value than surface energy treatments.
Practical next steps. Keep cleansing gentle (lukewarm water; bland emollient as a soap substitute), schedule a vaginal moisturiser 2–4 nights weekly, and match lubricant to your needs—water-based for versatility/condoms; silicone-based for the longest glide at a tender vestibule (avoid oil with latex). If considering a device, ask about intended use, UKCA/CE marking, expected timelines, and review points.
Evidence-Based Approaches
Cochrane Library: Cochrane reviews summarise evidence for energy-based vaginal therapies and related pelvic floor indications, highlighting small trials, short follow-up and heterogeneity—useful when weighing devices against established care (Cochrane Library – search vaginal laser/radiofrequency).
NICE guidance (UK): For GSM care sequencing—foundations and local hormonal therapy as first-line—see the NICE Menopause Guideline (NG23), which frames when adjuncts may be considered.
Regulatory and vigilance: UK information on medical device marking, intended use and safety reporting is provided by the national regulator; see the MHRA medical devices pages.
NHS patient information: Plain-English advice on symptoms, self-care and when to seek help for vaginal dryness helps anchor expectations and first steps before considering devices.
Peer-reviewed overviews: Public abstracts indexed on PubMed discuss GSM mechanisms and device evidence (including sham-controlled trials and durability questions), supporting shared decision-making.